Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: INmune Bio Q2 Adj. EPS $(0.34) Beats $(0.39) Estimate

Author: Benzinga Newsdesk | August 07, 2025 05:38pm
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 32 percent increase over losses of $(0.50) per share from the same period last year.

Posted In: INMB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist